Ronald S. Swerdloff, MD, MACP, discusses 2-year follow-up data from an open-label, multicenter study of Jatenzo (testosterone undecanoate) oral capsules in men with hypogonadism. The findings showed that Jatenzo kept testosterone levels in the normal range with a similar safety profile as other testosterone replacement therapies (TRTs). Of note, Swerdloff says that over the 2 years, Jatenzo showed “no evidence of liver toxicity,” whereas some TRTs have been associated with liver toxicities.
Swerdloff is a senior investigator at the Lundquist Institute, chief, Division of Endocrinology, Harbor-UCLA Medical Center, and professor of Medicine, David Geffen School of Medicine at UCLA.
Study highlights how DTC online platforms often fail to convey risks of testosterone therapy
December 8th 2022“While there’s benefit in improving access, there’s also potential for harm when providers fail to follow evidence-based guidelines, or when the benefits and risks of treatment are not appropriately communicated," said Joshua A. Halpern, MD.
Expert explains latest findings with oral softgel capsule for testosterone replacement therapy
November 11th 2021"We didn't see any clinically significant changes on the prostate gland, which is very important for the urologists who see people who have prostate cancer or prostate enlargement," says Ronald Swerdloff, MD.
Study supports use of androgen receptor inhibitors in older men with nmCRPC
July 26th 2021Researchers from the FDA’s Center for Drug Evaluation and Research determined that the benefits of androgen receptor inhibitors outweighed the risks in men aged ≥80 years with nonmetastatic castration-resistant prostate cancer.
2 Clarke Drive
Cranbury, NJ 08512